아시안메드

비상장계속사업자

Asianmed Co.,Ltd.

이종진

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

아시안메드

Business Reg. No. 2478602009 · CEO 이종진

I.Investment Overview

Target아시안메드 (2478602009)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명아시안메드
영문명Asianmed Co.,Ltd.
대표자이종진
사업자등록번호2478602009
법인등록번호1101117375515
설립일2020.02.03
종업원수21명

V.Workforce

21

Current headcount · 2026.07 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW176.12021185.42022216.320232192024286.62025
영업이익100M KRW15.9202112.2202221.7202314.3202422.32025
순이익100M KRW13.4202110.4202217.4202311.4202418.12025
Item20252024202320222021
자산총계182.1억원154.5억원173.8억원158.9억원155.4억원
부채총계107.6억원98억원128.6억원131.1억원138억원
자본총계74.6억원56.5억원45.1억원27.8억원17.4억원
매출액286.6억원219억원216.3억원185.4억원176.1억원
영업이익22.3억원14.3억원21.7억원12.2억원15.9억원
순이익18.1억원11.4억원17.4억원10.4억원13.4억원

VII.Financial Ratios

FY2025 basis

7.79%

영업이익률

6.31%

순이익률

9.93%

ROA

24.24%

ROE

144.2%

부채비율

40.95%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

아시안메드 투심보고서 | Alpha Lenz